Ligand Pharmaceuticals Incorporated (LGND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.18B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ligand Pharmaceuticals Incorporated (LGND) Competitors
The companies most similar to Ligand Pharmaceuticals are Ionis Pharmaceuticals (IONS), Protagonist Therapeutics (PTGX) and Scholar Rock Holding (SRRK). Ligand Pharmaceuticals trades at 66.5x earnings, against a median of 87.2x for the 3 of these companies with a P/E. By market cap, Ligand Pharmaceuticals ranks 5th of the 13 companies on this page; Madrigal Pharmaceuticals (MDGL) is the largest at $9.93B.
Peer Comparison
LGND's ROIC of 0.1% is above the peer median of -36.3%, and its revenue growth of -31.8% is below the median of 44.9%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals (LGND) | $6.18B | 66.5x | 23.7x | 20.3% | 0.1% | -31.8% | 0.00% |
| Ionis Pharmaceuticals Inc (IONS) | $4.84B | N/A | 4.8x | -56.9% | -29.3% | 54.9% | 0.00% |
| Protagonist Therapeutics Inc (PTGX) | $8.55B | 27.7x | 15.8x | 62.0% | N/A | 5724.0% | 0.00% |
| Scholar Rock Holding Corp (SRRK) | $5.27B | N/A | N/A | 0.0% | -89.0% | -100.0% | 0.00% |
| Cogent Biosciences Inc (COGT) | $4.97B | N/A | N/A | 0.0% | -43.4% | -100.0% | 0.00% |
| Madrigal Pharmaceuticals Inc (MDGL) | $9.93B | N/A | 8.7x | -10.9% | -12.7% | 50.1% | 0.00% |
| Mirum Pharmaceuticals Inc (MIRM) | $6.14B | N/A | 8.9x | -134.7% | -133.6% | 39.6% | 0.00% |
| PTC Therapeutics Inc (PTCT) | $5.30B | N/A | 5.2x | -9.2% | 18.1% | 69.6% | 0.00% |
| Dianthus Therapeutics Inc. (DNTH) | $5.17B | N/A | N/A | 0.0% | N/A | 205.6% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| Kodiak Sciences Inc (KOD) | $7.27B | N/A | N/A | 0.0% | -1481.8% | 0.0% | 0.00% |
| Edgewise Therapeutics Inc (EWTX) | $5.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $5.29B | 87.2x | 8.7x | 0.0% | -36.3% | 44.9% | 0.00% |
Similar Companies
These are the 12 companies most similar to Ligand Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ionis Pharmaceuticals Inc (IONS) | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California. | IONS competitors |
| Protagonist Therapeutics Inc (PTGX) | Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical... | PTGX competitors |
| Scholar Rock Holding Corp (SRRK) | Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious... | SRRK competitors |
| Cogent Biosciences Inc (COGT) | Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. | COGT competitors |
| Madrigal Pharmaceuticals Inc (MDGL) | Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates... | MDGL competitors |
| Mirum Pharmaceuticals Inc (MIRM) | Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies... | MIRM competitors |
| PTC Therapeutics Inc (PTCT) | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. | PTCT competitors |
| Dianthus Therapeutics Inc. (DNTH) | Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops... | DNTH competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| Kodiak Sciences Inc (KOD) | Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing... | KOD competitors |
| Edgewise Therapeutics Inc (EWTX) | Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. | EWTX competitors |
Frequently Asked Questions About LGND
Who are Ligand Pharmaceuticals' main competitors?
The companies most similar to Ligand Pharmaceuticals include Ionis Pharmaceuticals (IONS), Protagonist Therapeutics (PTGX), Scholar Rock Holding (SRRK), Cogent Biosciences (COGT) and Madrigal Pharmaceuticals (MDGL), listed from the closest match.
Who is Ligand Pharmaceuticals' biggest competitor?
Madrigal Pharmaceuticals (MDGL) is the largest of the similar companies at $9.93B; Ionis Pharmaceuticals (IONS) is the closest match by business profile, size, sector and industry.
How does LGND stock compare with its competitors?
LGND's P/E is 66.5x against a peer median of 87.2x; its P/S is 23.7x against a peer median of 8.7x; its net margin is 20.3% against a peer median of 0.0%.
Which of Ligand Pharmaceuticals' competitors pays a higher dividend?
Ligand Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Ligand Pharmaceuticals bigger than its competitors?
No. Ligand Pharmaceuticals is 5th by market cap among the 13 companies on this page; the largest is Madrigal Pharmaceuticals (MDGL) at $9.93B.
LGND pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors